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Introduction
Intraductal papillary mucinous
neoplasms (IPMN) are uncommon
tumors arising from the main pancreatic
duct, branching pancreatic ducts, or both.
The “overall incidence of invasive
carcinoma associated with resected IPMN
has been reported to be 20-40%” (Mohri
et al., 2011). Due to their malignant
potential, these lesions, along with
mucinous cystic neoplasms (MCN), are
considered more worrisome, and often
require surgical resection (Gallucci,
Langellotto, De Ritis, & Uomo, 2012).
Even after removal of a primary lesion,
patients remain under surveillance to
monitor for recurrence, the rate of which
is approximately 6 % (Gallucci et al.,
2012), and patients with main duct IPMN
are at a higher risk for developing
pancreatic , gastric and colon
adenocarcinoma over their lifetimes
(Sheth, Howell & Kent, 2014).
While both main duct and side branch
lesions are considered pre-malignant,
management of IPMN has not been wellestablished (Mohri et al., 2011) and
ranges from watchful waiting to surgical
resection, depending upon the suspicion
of malignancy, the operation required
and the relative risk to the patient. A
lower threshold for surgical resection is
present for main duct IPMNs, as they
have a higher risk of associated
malignancy (Sahora & Castillo, 2014).
The incidence of pancreatic
adenocarcinoma arising from IPMN has
been well documented (Mohri et al.,
2011). This poster discusses one such
case. The patient’s IPMN was initially
discovered incidentally, during
evaluation of an unrelated medical
diagnosis.
As practitioners, it is important to be
able to recognize IPMN as pre-malignant
lesions and to act quickly to identify
patients requiring further work-up. Since
the prognosis of pancreatic
adenocarcinoma is dismal, the early
identification and treatment of IPMN, or
pre-malignant lesions is imperative to
improve outcomes (Mohri et al., 2011).

Surveillance imaging for her FNH
noted a small, cystic lesion in the body of
the pancreas measuring 0.6 centimeters.
No follow up was done for this lesion.
In 2014 surveillance imaging, the
patient’s pancreatic cyst had increased
in size to one centimeter and new
pancreatic duct dilation and irregularity
was described, as well as an appearance
of chronic pancreatitis. Mild symptoms
were present at this time, including
abdominal cramping and bloating. No
jaundice, weight loss or fatigue were
reported.
She underwent an endoscopic
ultrasound at this time, which
demonstrated no significant abnormality
in the pancreas. An abrupt change in the
distal body and tail, distal to a focal
calcification was described. This was
suggestive of inflammation. Cysts
measuring as large as 12 mm were
noted, and fine needle aspiration was
performed. The fluid was thin and
blood-tinged.
Cytology results demonstrated no
evidence of malignancy or mucin, and
cyst fluid analysis for amylase and CEA
were unable to be performed due to an
inadequate amount of fluid.
The patient was seen in surgical
consultation and elected to undergo the
recommended surgical resection via
distal pancreatecomy with splenectomy.
Final pathology revealed a 1.5
centimeter pancreatic tumor positive for
moderately differentiated pancreatic
ductal adenocarcinoma arising in
intraductal pancreatic mucinous
neoplasm with high-grade dysplasia
involving the main duct and branches
(mixed type). Of the 14 lymph nodes that
were evaluated, zero were positive for
adenocarcinoma.

Signs & Symptoms
Patients with main duct and side
branch IPMNs are often asymptomatic.
Symptoms can include, abdominal
discomfort and/or distress, vomiting,
back pain, or signs of chronic
pancreatitis (Grützmann, Post, Saeger, &
Niedergethmann, 2011). Though
uncommon, IPMN can cause mild acute
pancreatitis (Jang et al., 2013).
Symptoms predictive of malignancy
include jaundice, weight loss or diabetes
(Gallucci et al., 2012).
Radiographic evidence of IPMN
includes the presence of a cystic lesion
with a dilated main duct and evidence of
communication between the cyst and the
duct. MRI is more sensitive for detecting
a mural nodule, which is considered a
“strong predictive factor for malignancy”
(Uehara et al., 2011).
Signs of IPMN on endoscopic
ultrasonography include the presence of
papillary growth in the ducts of the
pancreas, communication between the
cyst and the duct (either main or
branch), and/or a clearly dilated main
duct (Grutzmann et al., 2011) with or
without the presence of mucin within
the duct. (Gallucci et al., 2012). Presence
of mucin in the duct can have the classic
“fish eye” appearance. Fine needle
aspiration often demonstrates atypical
cells or mucin, and laboratory evaluation
of CEA levels greater than 2500 ng/mL
are considered diagnostic. (Grutzmann
et al., 2011) .

Endoscopic Ultrasound often shows mucin arising from the main pancreatic duct,
giving a “fish eye” appearance.

Case Presentation
The patient is a 51 year-old female who
was noted to have multiple liver lesions
at the time of imaging for her
cholecystectomy several years ago. She
was under surveillance for these liver
lesions, which were felt to be focal
nodular hyperplasia (FNH).

Margins were negative. The final staging
was T1N0 (stage IA). The patient was
referred to medical oncology and
chemotherapy was recommended.

Courtesy of Mark Bloomston, MD

Pathophysiology of IPMN
IPMNs arise from the pancreatic ductal
epithelium. The columnar epithelial
tumor cells secrete mucin, leading to the
dilation of the pancreatic duct and the
associated symptoms of abdominal pain
and pancreatitis. Intraductal papillary
growth is also present. Cellular changes
within the IPMN can vary from slight
mucinous hyperplasia to invasive
adenocarcinoma (Capurso et al., 2013).
The cause of the development of IPMN is
not fully understood., though they have
been linked to several molecular changes.

According to Gallucci et al. (2012)
mutation of K-ras, an oncogene responsible
for regulating the division of cells, is
present in up to 65% of IPMNs. Other
molecular abnormalities include alterations
in CDKN2a, ring finger protein 43 gene,
SMAD4, STK11, MUC1, 2, and 5, and
promoter sequence hypermethylation
(Sheth, Howell & Kent, 2014).
The pathophysiology of IPMN is
significant because the cellular changes are
often atypical and can progress to an
invasive pancreatic adenocarcinoma, the 5year survival rate of which is 1-14%
(American Cancer Society, 2014).

Implications for
Nursing Care
As advanced practice nurses, it is
important to consider incidental imaging
findings and their clinical significance. In
the case of incidental pancreatic findings,
referral to pancreatologists or surgical
oncologists is critical, as early detection
of premalignant lesions will lead to
increases in survival for many patients.
Attention to vague symptoms, such as
persistent abdominal complaints should
be followed closely and IPMN should be
in the differential diagnosis, especially
when other causes have been ruled out.
Additional consideration should also
be given to patients with a history of
IPMN. Given their overall increased risk
of both colon and gastric cancer, routine
screenings, including upper and lower
endoscopy, should be considered for
these patients, though they may not be
the recommended age for such testing.

Conclusion

The cystic structure in the distal pancreas appears to arise from the main
pancreatic duct.
Courtesy of Mark Bloomston, MD

Possible Molecular Abnormalities in IPMN
K-ras: Responsible for normal tissue signaling, K-ras is a protein that binds to
GTP and referees signal transduction. Mutations in K-ras is present in up to 65%
of IPMNs.
•
CDKN2a: Mutations in this tumor suppressor gene have been associated with
IPMN.
•
Ring finger protein 43: This protein plays a role in suppressing mucus
producing neoplasia of the pancreas. Mutations that inactivate this gene have
been associated with IPMN.
•
SMAD4: Intracellular proteins that code and transcribe extracellular signals in
the nucleus. Expression of SMAD4 is present in most IPMNs.
•
STK11: This gene, which acts as a tumor suppressor, is mutated in patients with
Peutz-Jeghers syndrome. A subset of these patients have a higher risk of both
IPMN and pancreatic cancer.
•
MUC: These mucin mRNA, particularly MUC 1,2, and 5are highly expressed in
approximately 86% of IPMN. MUC1 and MUC2 are associated with malignancy.
•
Promoter sequence hypermethylation: This process can cause gene silencing.
Hypermethylation of tumor suppressor genes has been seen in patients with
IPMN with greater degrees of dysplasia or even cancer.
(Sheth, Howell & Kent, 2014)
•

IPMNs are precursors to invasive
pancreatic adenocarcinoma. Recognizing
their clinical significance is essential in
practice and educating patients about
their implication is a responsibility of the
practitioner. Management of these
premalignant lesions varies greatly
depending upon subtype, patient age,
comorbidities and morbidity of required
surgery. Close surveillance with MRI and a
multidisciplinary approach may be the
preferred management for some patients,
particularly those without suspicious
findings (Roch et al., 2014).
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